# The ONE Study nTreg Trial (ONEnTreg13)

> **NCT02371434** · PHASE1,PHASE2 · COMPLETED · sponsor: **Prof. Dr. Petra Reinke** · enrollment: 17 (actual)

## Conditions studied

- Immunosuppressive Treatment of Living-donor Renal Transplantation

## Interventions

- **BIOLOGICAL:** autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)

## Key facts

- **NCT ID:** NCT02371434
- **Lead sponsor:** Prof. Dr. Petra Reinke
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-11-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02371434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02371434, "The ONE Study nTreg Trial (ONEnTreg13)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02371434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*